A look at resmetirom and the upcoming 52 week biopsy results of the phase 3 MAESTRO-NASH trialTicker(s): MDGL, LLY, AKRO, ICPT
Institution: Yale University
- Academic hepatologist, Associate Professor of Medicine (Digestive Diseases) and Director, Yale Viral Hepatitis Program.
- Treats patients with chronic liver diseases including the entire spectrum from cirrhosis, liver failure, and post-transplant; Approximately 5-10% of his patients have chronic pruritus symptoms, 200 patients with biopsy-proven NASH and a larger cohort of NAFLD, and 70 patients with PBC/PSC.
- Has served on the national steering committees for large observational cohort studies for liver disease and has published over 100 papers in the area of GI and liver diseases.
Maybe we could just start a bit with your practice background, your research split and your clinical involvement, clinical study involvement you have currently.Added By: wilson_admin
Can you discuss current NASH clinical treatment paradigm as you see it, what therapies and lifestyle modifications are recommended, in what order, and what remaining unmet needs you primarily see.Added By: wilson_admin
Great, maybe, let’s get the elephant out of the room early, what are your thoughts on the data we’ve seen on tirzepatide so far, it does seem like the additional weight loss observed there is impressive.Added By: wilson_admin
What were your thoughts on the failed phase 2 for semaglutide back in the summer? It was shocking how bad the data was, do you think the F4 stage of the patients or 29% placebo rate had anything to do with it?Added By: wilson_admin
Has that affected your enthusiasm at all for GIP/GLP dual agonist approach, whether on cirrhotic patients or not?Added By: wilson_admin
Moving onto the Madrigal drug, on a high level, what are your thoughts about the mechanism of resmetirom? Clearly it’s defatting the liver, improving liver enzymes, and helping with metabolic syndromeAdded By: wilson_admin
Discussing the MAESTRO-NASH trial. They’ve split the co-primary between NASH resolution and fibrosis, patients have fibrosis stage 1b, 2 or 3. I guess, just from your perspective, let’s say they hit on resolution but not on fibrosis, how would that affect your enthusiasm for the drug? Assuming it was approved, would you still use it?Added By: wilson_admin
What are your thoughts on the fibrosis endpoint? Do you think 52 weeks is enough time to show a benefit?Added By: wilson_admin
Another concern I had is with the ballooning definition, there was a recent paper using HistoIndex (Dr. Brunt), which is an AI histology company. There was a substantial divergence in hepatocyte ballooning identified amongst expert hepatopathologists suggests that ballooning is a spectrum, so it might be too subjective to be used unequivocally as an endpoint. And I guess there is also intrinsic variability in the biopsy sample. What are your thoughts on that?Added By: wilson_admin
Regardless of how the biopsy data reads out, we are still going to be waiting on the 54 month composite clinical outcome endpoint. Obviously this is still very far out, but I’m wondering what degree of confidence you have that there would be a positive outcomes benefit, and over what period of time you think you would need before the curves begin to separate meaningfully.Added By: wilson_admin
Madrigal also initiated the MAESRO-NASH Outcomes study in August, 700 patients with early Nash cirrhosis, monitoring for progression to liver decompensation events. What are your thoughts on the odds of a positive study, given the level of disease in these patients?Added By: wilson_admin
If you had to, what % probability would you assign that both primary endpoints are hit for MAESTRO-NASH?Added By: wilson_admin
What are your thoughts on FXR agonism? Even if Ocaliva does get the approval in NASH, do you think this is a drug that would be used much, or is the pruritus just too much of an issue?Added By: wilson_admin
Are you familiar with the data Akero released on their FGF21 analogue? The data read positive , but there was significant dropouts in the treatment arms. If you used ITT it seems like this would have missed on stat sig, and of course the BMY FGF21 failed their mid stage trial last year.Added By: wilson_admin
Are there any other mechanisms I haven't discussed that you think are interesting for therapies in NASH?Added By: wilson_admin
Overall, can you rate your enthusiasm out of 10 for the various mechanisms, including GIP/GLP, THR-Beta, FXR, and FGF21? And can you provide high level comments on potential for combination use?Added By: wilson_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.